Anam Fatima, Muhammad Aamir, Naila Shahbaz, Shehla Akbar, Adeel Aslam, Kashif Barkat, Samia Afaq
{"title":"巴基斯坦单一中心接受超说明书药物治疗的心脏病患儿药物相互作用的患病率:一项横断面研究。","authors":"Anam Fatima, Muhammad Aamir, Naila Shahbaz, Shehla Akbar, Adeel Aslam, Kashif Barkat, Samia Afaq","doi":"10.1136/bmjpo-2024-003293","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluated the prevalence of clinically significant drug-drug interactions (CSDDIs), off-label (OL) drug use and the associated predictors in paediatric cardiology ward.</p><p><strong>Design: </strong>A cross-sectional study.</p><p><strong>Setting: </strong>Hayatabad Medical Complex, Tertiary care hospital in Peshawar, Pakistan.</p><p><strong>Patients: </strong>250 patients.</p><p><strong>Methodology: </strong>The Micromedex Drug-Reax tool was used to check the drug-drug interactions (DDI) and interactions of major severity were categorised as CSDDI. Association of various predictors including OL drug use with CSDDIs was evaluated using univariate and multivariate binary logistic regression.</p><p><strong>Main outcome measures: </strong>Rate of drug-drug interactions, types and classification of DDI, OL prescribing in paediatrics.</p><p><strong>Result: </strong>Of the total 250 paediatric patients, 127 (28.6%) patients were exposed to at least one clinically significant DDI, while 228 (91.20%) patients received at least one OL prescription. Furosemide was the most frequently prescribed drug involved in CSDDIs, while it was also one of the highly prescribed OL drugs. Multivariate analysis revealed that infant age group (OR 0.256; CI 0.080 to 0.814) with p value 0.02 and patients prescribed >5 drugs (OR 3.544; CI 1.906 to 6.589) were significantly more likely to experience CSDDIs in reference to their corresponding categories.</p><p><strong>Conclusion: </strong>A high prevalence of CSDDIs and OL prescriptions was observed. OL drug presence was also observed to be a significant predictor associated with an increased risk of CSDDIs. Thus, to improve paediatric pharmacotherapy, suitable medical interventions are required to decrease OL drug use and CSDDIs.</p>","PeriodicalId":9069,"journal":{"name":"BMJ Paediatrics Open","volume":"9 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12434784/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence of drug-drug interactions in children with cardiac disorders receiving off-label drugs in a single centre in Pakistan: a cross-sectional study.\",\"authors\":\"Anam Fatima, Muhammad Aamir, Naila Shahbaz, Shehla Akbar, Adeel Aslam, Kashif Barkat, Samia Afaq\",\"doi\":\"10.1136/bmjpo-2024-003293\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This study evaluated the prevalence of clinically significant drug-drug interactions (CSDDIs), off-label (OL) drug use and the associated predictors in paediatric cardiology ward.</p><p><strong>Design: </strong>A cross-sectional study.</p><p><strong>Setting: </strong>Hayatabad Medical Complex, Tertiary care hospital in Peshawar, Pakistan.</p><p><strong>Patients: </strong>250 patients.</p><p><strong>Methodology: </strong>The Micromedex Drug-Reax tool was used to check the drug-drug interactions (DDI) and interactions of major severity were categorised as CSDDI. Association of various predictors including OL drug use with CSDDIs was evaluated using univariate and multivariate binary logistic regression.</p><p><strong>Main outcome measures: </strong>Rate of drug-drug interactions, types and classification of DDI, OL prescribing in paediatrics.</p><p><strong>Result: </strong>Of the total 250 paediatric patients, 127 (28.6%) patients were exposed to at least one clinically significant DDI, while 228 (91.20%) patients received at least one OL prescription. Furosemide was the most frequently prescribed drug involved in CSDDIs, while it was also one of the highly prescribed OL drugs. Multivariate analysis revealed that infant age group (OR 0.256; CI 0.080 to 0.814) with p value 0.02 and patients prescribed >5 drugs (OR 3.544; CI 1.906 to 6.589) were significantly more likely to experience CSDDIs in reference to their corresponding categories.</p><p><strong>Conclusion: </strong>A high prevalence of CSDDIs and OL prescriptions was observed. OL drug presence was also observed to be a significant predictor associated with an increased risk of CSDDIs. Thus, to improve paediatric pharmacotherapy, suitable medical interventions are required to decrease OL drug use and CSDDIs.</p>\",\"PeriodicalId\":9069,\"journal\":{\"name\":\"BMJ Paediatrics Open\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12434784/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Paediatrics Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjpo-2024-003293\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Paediatrics Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjpo-2024-003293","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究评估儿科心脏病病房临床显著药物-药物相互作用(csddi)、超说明书(OL)药物使用的患病率及其相关预测因素。设计:横断面研究。地点:巴基斯坦白沙瓦的Hayatabad综合医疗中心,三级保健医院。患者:250名患者。方法:采用Micromedex Drug-Reax工具检查药物-药物相互作用(DDI),将严重程度的相互作用归类为CSDDI。使用单变量和多变量二元逻辑回归评估包括OL药物使用在内的各种预测因素与csddi的关联。主要观察指标:药物相互作用率、DDI的类型和分类、儿科OL处方。结果:在250例儿童患者中,127例(28.6%)患者至少使用过一种具有临床意义的DDI, 228例(91.20%)患者至少使用过一种OL处方。速尿是csddi中最常见的处方药物,同时也是高处方的OL药物之一。多因素分析显示,婴儿年龄组(OR = 0.256, CI = 0.080 ~ 0.814, p值为0.02)和bbb50类药物患者(OR = 3.544, CI = 1.906 ~ 6.589)发生csddi的可能性明显高于相应类别。结论:csddi和OL处方的患病率较高。OL药物的存在也被观察到是与csddi风险增加相关的重要预测因子。因此,为了改善儿科药物治疗,需要适当的医疗干预措施来减少OL药物使用和csddi。
Prevalence of drug-drug interactions in children with cardiac disorders receiving off-label drugs in a single centre in Pakistan: a cross-sectional study.
Objectives: This study evaluated the prevalence of clinically significant drug-drug interactions (CSDDIs), off-label (OL) drug use and the associated predictors in paediatric cardiology ward.
Design: A cross-sectional study.
Setting: Hayatabad Medical Complex, Tertiary care hospital in Peshawar, Pakistan.
Patients: 250 patients.
Methodology: The Micromedex Drug-Reax tool was used to check the drug-drug interactions (DDI) and interactions of major severity were categorised as CSDDI. Association of various predictors including OL drug use with CSDDIs was evaluated using univariate and multivariate binary logistic regression.
Main outcome measures: Rate of drug-drug interactions, types and classification of DDI, OL prescribing in paediatrics.
Result: Of the total 250 paediatric patients, 127 (28.6%) patients were exposed to at least one clinically significant DDI, while 228 (91.20%) patients received at least one OL prescription. Furosemide was the most frequently prescribed drug involved in CSDDIs, while it was also one of the highly prescribed OL drugs. Multivariate analysis revealed that infant age group (OR 0.256; CI 0.080 to 0.814) with p value 0.02 and patients prescribed >5 drugs (OR 3.544; CI 1.906 to 6.589) were significantly more likely to experience CSDDIs in reference to their corresponding categories.
Conclusion: A high prevalence of CSDDIs and OL prescriptions was observed. OL drug presence was also observed to be a significant predictor associated with an increased risk of CSDDIs. Thus, to improve paediatric pharmacotherapy, suitable medical interventions are required to decrease OL drug use and CSDDIs.